Human Ubiquitin+1 Antibody
R&D Systems, part of Bio-Techne | Catalog # MAB7031
Key Product Details
Species Reactivity
Validated:
Human
Applications
ELISA Capture (Matched Antibody Pair), Western Blot
Label
Unconjugated
Antibody Source
Monoclonal Mouse IgG2B Clone # 83456
Product Summary for Human Ubiquitin+1 Antibody
Immunogen
E. coli-derived recombinant human Ubiquitin+1
Met1-Gly75, YADLREDPDRQDHHPGSGAQ (C-terminal sequence generated by a frameshift)
Accession # CAA44911
Met1-Gly75, YADLREDPDRQDHHPGSGAQ (C-terminal sequence generated by a frameshift)
Accession # CAA44911
Specificity
Detects human Ubiquitin+1 in ELISAs and Western blots. In in ELISAs and Western blots, no cross-reactivity with Ubiquitin is observed.
Clonality
Monoclonal
Host
Mouse
Isotype
IgG2B
Applications for Human Ubiquitin+1 Antibody
Application
Recommended Usage
Western Blot
1 µg/mL
Sample: Recombinant Human Ubiquitin+1 (Catalog # 703-UB)
Sample: Recombinant Human Ubiquitin+1 (Catalog # 703-UB)
Human Ubiquitin+1 Sandwich Immunoassay
Please Note: Optimal dilutions of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Protein A or G purified from hybridoma culture supernatant
Reconstitution
Reconstitute at 0.5 mg/mL in sterile PBS. For liquid material, refer to CoA for concentration.
Formulation
Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
Shipping
Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.
Stability & Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Background: Ubiquitin+1
Ubiquitin+1 has a carboxyl terminal amino acid sequence that differs from normal Ubiquitin. The different carboxyl terminal sequence appears to result from a frameshift in the Ubiquitin mRNA. The underlying mechanisms creating the mRNA frameshift are not clearly understood. The occurrence of the frameshift that generates Ubiquitin+1 is much more prevalent in patients with Alzheimers Disease or with Down Syndrome than in control individuals who are not afflicted with the disorders. The monoclonal anti-Ubiquitin+1 (Catalog # MAB703) and rabbit polyclonal anti-Ubiquitin+1 (Catalog # AF703) antibodies were raised against the Ubiquitin+1 carboxyl terminal sequence that differs from normal Ubiquitin and are therefore non-reactive with Ubiquitin. Monoclonal anti-Ubiquitin (Catalog # MAB701) detects both Ubiquitin and Ubiquitin+1 indicating that the epitope recognized by this antibody is contained in the portion of the proteins that are identical (1, 2).
References
- van Leeuwen, F.W. et al. (1998) Science 279:242.
- van Leeuwen, F.W. et al. (1998) Trends Neurosci. 21:331.
Long Name
frame shift mutant
Alternate Names
FLJ25987, MGC8385, polyubiquitin B, polyubiquitin-B, RPS27A, UBA52, UBC, ubiquitin B
Gene Symbol
UBB
UniProt
Additional Ubiquitin+1 Products
Product Documents for Human Ubiquitin+1 Antibody
Product Specific Notices for Human Ubiquitin+1 Antibody
For research use only
Loading...
Loading...
Loading...
Loading...